New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTBCS, AZNAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
06:41 EDTAZNAstraZeneca upgraded to Buy from Hold at HSBC
HSBC upgraded AstraZeneca to Buy based on recent shares weakness and a large amount of Oncology and ImmunoOncology news flow in the coming months.
06:38 EDTBCSMorgan Stanley poaches two brokers from Citigroup, Reuters reports
Morgan Stanley (MS) has poached two brokers from Citigroup's (C) private banking unit, William Goettert and John Entenberg, who managed $1B in client assets and have a combined $5M in production, Reuters reports. Additionally, Morgan Stanley has hired Louis Greif from Barclays' (BCS) U.S. wealth and investment management unit. Reference Link
September 1, 2015
08:33 EDTAZNNektar receives $40M milestone payment from first commercial sale of Moventig
Nektar (NKTR) announced that it has received a $40M cash payment under a license agreement with AstraZeneca (AZN). The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. MOVENTIG is the first once-daily, oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication approved in the European Union for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. MOVENTIG is marketed in the U.S. by AstraZeneca as MOVANTIK and is the first once-daily oral PAMORA medication indicated for the treatment of OIC in adult patients with chronic, non-cancer pain. MOVENTIG/MOVANTIK is part of the exclusive worldwide license agreement announced on September 21, 2009 between AstraZeneca and Nektar Therapeutics. Under the terms of the agreement, in addition to the $40 million milestone payment announced today, Nektar received a $100 million milestone payment upon first commercial sale of MOVANTIK in the U.S. in March of 2015. Nektar is also entitled to royalties on worldwide net product sales and up to $375 million in sales milestones. The royalty rate in the U.S. starts at 20% and escalates. The royalty rate in Europe and the rest of the world starts at 18% and escalates. Under the agreement, AstraZeneca is responsible for all sales and marketing activities for MOVANTIK worldwide.
05:33 EDTAZNValeant, AstraZeneca to partner on brodalumab
Valeant Pharmaceuticals (VRX) announced that its affiliate has entered into a collaboration agreement with AstraZeneca (AZN) under which Valeant was granted an exclusive license to develop and commercialize brodalumab. Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin under a prior arrangement with Amgen Inc., the originator of brodalumab. Valeant will assume all development costs associated with the regulatory approval for brodalumab. Regulatory submission in U.S. and EU for brodalumab in moderate-to-severe psoriasis is planned for Q4. Under the terms of the agreement, Valeant will make an up-front payment to AstraZeneca of $100M, as well as additional pre-launch milestones of up to $170M and further sales-related milestone payments of up to $175M following launch. After approval, AstraZeneca and Valeant will share profits.
August 31, 2015
06:35 EDTBCSCiti plans to rebuild equities franchise, Reuters reports
Citigroup (C) is planning to rebuild its equities franchise in an effort to capitalize on a retrenchment by rivals in the face of new rules created to make the financial system less risky, Reuters reports, citing people familiar with the bank's plans. It may be tough to overcome leaders such as Goldman Sachs (GS), Morgan Stanley (MS), and JPMorgan Chase (JPM), that have long dominated the sector, the report says. Citi is aiming to profit from a retreat of rivals slow to adapt new rules forcing banks to keep more capital, the report says. Deutsche Bank (DB), Credit Suisse (CS), and Barclays (BCS) are among others rebuilding their investment banking businesses, the report adds. Reference Link
06:10 EDTBCSBanks lobby EU over privacy rules overhaul, FT reports
Subscribe for More Information
August 27, 2015
07:57 EDTBCSPlatts to hold a conference
Subscribe for More Information
07:51 EDTAZNRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
06:13 EDTBCSJudge throws out HFT suit against Barclays, exchanges, FT reports
A U.S. judge has dismissed investor lawsuits against Barclays and certain U.S. exchanges alleging that the bank rigged its "dark pool" trading venue in favor of high-frequency traders, the Financial Times reports. The judge ruled that the plaintiffs did not claim any actions meeting the definition of "manipulative acts," the report says. Reference Link
August 24, 2015
05:13 EDTAZNAstraZeneca to collaborate with Peregrine on cancer immunotherapy clinical trial
Subscribe for More Information
August 23, 2015
12:35 EDTAZNBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 20, 2015
11:33 EDTAZNLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
09:23 EDTAZNAdvaxis, MedImmune begin enrollment in axalimogene filolisbac Phase I/II study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use